The European Commission’s Pharmaceutical Sector Inquiry raised significant concerns regarding so-called “reverse payment” patent settlement agreements. In this article, CRA describes the types of information or economic evidence that might facilitate evaluation of the competitive aspects of these settlements. To read the article, click here:
SEP licensing in the United States: Understanding the impact on US business
US Business Survey On behalf of ACT | The App Association, consultants with Charles River Associates undertook a survey of US businesses that use technical...